Back to the Top
The following message was posted to: PharmPK
We have some NCEs with good in vitro anti-inflammatory
activity. We want to develop them by oral
administrtion for disease conditions like inflammatory
bowel disease (IBD) and rheumatoid arthritis (RA).
Does the bioavailability of these compounds determine
in which inflammatory diseases they can be developed.
If the F is high (>80%), should it be developed for
RA? If the F is low (10-20%), should it be developed
only for IBD, for local anti-inflammatory action on
the intestine?
Any references will be highly appreciated.
Thanks
Ananda
Back to the Top
The following message was posted to: PharmPK
We have some NCEs with good in vitro anti-inflammatory
activity. We want to develop them by oral
administrtion for disease conditions like inflammatory
bowel disease (IBD) and rheumatoid arthritis (RA).
Does the bioavailability of these compounds determine
in which inflammatory diseases they can be developed.
If the F is high (>80%), should it be developed for
RA? If the F is low (10-20%), should it be developed
only for IBD, for local anti-inflammatory action on
the intestine?
Any references will be highly appreciated.
Thanks
Ananda
[Sorry if this is a repeat - db]
Back to the Top
The following message was posted to: PharmPK
Dear Anana ,
The route of administartion will be decided primarily with objective of
safety and the efficacy of the drug product. With a low oral
bioavialability also if you are able to prove efficacy of the drug
product
there is nothing harm in chosing oral route. Further for developiong
a drug
product for rheumatoid arthritis (RA)one should also look at the
volume of
distribution of the drug product after oral administration. Generally
the
drug product which are chosen for the these knid of disease have high
volume of distribution and slow elimination . Hope this helps you to
some
extent.
Regards
Manoj Kumar Vishwakarma
Group- Leader
Biopharmaceutics
Back to the Top
The following message was posted to: PharmPK
Dear Anana ,
The route of administartion will be decided primarily with objective of
safety and the efficacy of the drug product. With a low oral
bioavialability also if you are able to prove efficacy of the drug
product
there is nothing harm in chosing oral route. Further for developiong
a drug
product for rheumatoid arthritis (RA)one should also look at the
volume of
distribution of the drug product after oral administration. Generally
the
drug product which are chosen for the these knid of disease have high
volume of distribution and slow elimination . Hope this helps you to
some
extent.
Regards
Manoj Kumar Vishwakarma
Group- Leader
Biopharmaceutics
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)